Sign in

You're signed outSign in or to get full access.

R

Rohit

Research Analyst at Morgan Stanley

Mumbai, MH, IN

Rohit Goenka is a Managing Director and Chief Financial Officer of Morgan Stanley’s Investment Management division, bringing extensive expertise in financial leadership and strategic management. Previously a sell-side equity research analyst, he covered large wealth and asset management firms, delivering in-depth analysis and playing a pivotal role in Investor Relations, the Firm Strategy and Execution Group, and Treasury. Since joining Morgan Stanley in 2005, Rohit has demonstrated strong performance across multiple leadership roles, though specific performance metrics are not publicly disclosed. He holds a Bachelor of Engineering from Birla Institute of Technology & Science, Pilani, and an MBA from the Indian School of Business, Hyderabad.

Rohit's questions to Mirum Pharmaceuticals (MIRM) leadership

Question · Q4 2025

Rohit asked about the current market for HDV, its expected development, and the anticipated increase in R&D expenses this year due to HDV studies.

Answer

CEO Chris Peetz described an evolving HDV landscape with no U.S.-labeled therapies but potential approvals for Hepcludex and other agents. He expressed excitement for brelovitug's potential best-in-class profile with impressive response rates. CFO Eric Bjerkholt stated that brelovitug's four Phase III studies are enrolling well, leading to an anticipated $150 million increase in R&D spend this year, with about half allocated to CMC investments for a BLA submission next year.

Ask follow-up questions

Fintool

Fintool can predict Mirum Pharmaceuticals logo MIRM's earnings beat/miss a week before the call

Question · Q3 2025

Rohit inquired about Mirum's perspective on the competitive dynamics in the PBC market, specifically in light of GSK's recent Linerixibat PDUFA announcement.

Answer

CEO Chris Peetz highlighted two key aspects: Volixibat's VANTAGE study incorporates both first and second-line PBC settings, including patients with stable alkaline phosphatase on UDCA but still experiencing itch, making them candidates for Volixibat. He also expressed excitement about Volixibat's competitive profile, citing the striking placebo-adjusted difference in itch observed in the VANTAGE interim data, which led to breakthrough designation.

Ask follow-up questions

Fintool

Fintool can write a report on Mirum Pharmaceuticals logo MIRM's next earnings in your company's style and formatting